不同的一线治疗方案对非小细胞肺癌患者的影响观察
2021-03-22梅耀国石玲李达
梅耀国 石玲 李达



【摘要】 目的:觀察分析不同的一线治疗方案对非小细胞肺癌患者的影响观察。方法:选择2019年1月-2021年2月于本院进行治疗的74例非小细胞肺癌患者作为研究对象。按照随机数字表法分为对照组和观察组,每组37例。对照组给予依托泊苷+顺铂治疗,观察组给予依托泊苷+安罗替尼治疗,比较两组临床治疗效果、血管内皮生长因子(VEGF)、肿瘤坏死因子(TNF-α)水平、肿瘤标记物水平及不良反应情况。结果:治疗后,观察组临床总有效率高于对照组(P<0.05);两组治疗后VEGF、TNF-α水平较治疗前均降低,且观察组均低于对照组(P<0.05);两组治疗后CEA、SCC、CYFRA21-1较治疗前均降低,且观察组均低于对照组(P<0.05)。两组咯血、咳嗽、呼吸困难以及口腔黏膜炎发生率比较,差异均无统计学意义(P>0.05)。结论:非小细胞肺癌患者一线治疗方案中采用安罗替尼+依托泊苷治疗具有明显效果,能有效缓解患者的临床症状,降低血清VEGF、TNF-α水平,降低肿瘤标志物水平,且不增加不良反应,值得临床推广及应用。
【关键词】 安罗替尼 非小细胞肺癌 依托泊苷 肿瘤标志物
Effect of Different First-line Treatments on Patients with Non-small Cell Lung Cancer/MEI Yaoguo, SHI Ling, LI Da. //Medical Innovation of China, 2021, 18(30): 0-028
[Abstract] Objective: To observe and analyze the effects of different first-line treatments on patients with non-small cell lung cancer. Method: From January 2019 to February 2021, 74 patients with non-small cell lung cancer treated in our hospital were selected as the research subjects. They were divided into the control group (n=37) and the observation group (n=37) by random number table method. The control group was given Etoposide + Cisplatin treatment, the observation group was given Etoposide + Anlotinib treatment. The clinical treatment effects, vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-α) levels, tumor markers levels and adverse reactions of two groups were compared. Result: After treatment, the total clinical effective rate of the observation group was higher than that of the control group (P<0.05). The VEGF and TNF-α levels of two groups after treatment decreased compared with before treatment, and the observation group were significantly lower than those of the control group (P<0.05). The CEA, SCC, CYFRA21-1 of two groups after treatment decreased compared with before treatment, and the observation group were lower than those of the control group (P<0.05). The incidence of hemoptysis, cough, dyspnea and oral mucosa inflammation of two groups compared, there were no significant differences (P>0.05). Conclusion: The use of Anlotinib + Etoposide in the first-line treatment plan for patients with non-small cell lung cancer has a significant effect, which can effectively alleviate the clinical symptoms of patients, reduce the levels of serum VEGF and TNF-α, and reduce tumor-related markers, and not increase adverse reactions, it is worthy of clinical promotion and application.
[Key words] Anlotinib Non-small cell lung cancer Etoposide Tumor markers
First-authors address: Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang 332000, China
doi:10.3969/j.issn.1674-4985.2021.30.006
非小细胞肺癌是临床中最为多见的肺癌类型之一,是起源于支气管黏膜、支气管腺体和肺泡上皮的一类肺恶性肿瘤性疾病,可分为腺癌、鳞状细胞癌、腺鳞癌、大细胞癌及肉瘤样癌等亚型[1-2]。早期肺癌患者一般无明显典型症状,中晚期患者则根据原发病灶位置的不同、是否有胸内播散、远处转移灶等情况,可出现咳嗽、咳痰或咯血、呼吸困难或喘鸣、发热、体重明显下降、声音异常、胸腔积水等不同症状[3-4]。由于大部分患者在发现非小细胞肺癌时已进入晚期,错过了最佳的手术时机,只能采取化疗手段来控制病情发展[5]。近几年来,大量临床研究表明,安罗替尼在非小细胞肺癌患者治疗中具有明显疗效,但用于一线治疗的相关报道较少。……
